Zoetis UKは、犬の骨関節炎に伴う疼痛緩和を目的とした長時間作用型モノクローナル抗体製剤「Lenivia」（一般名：izenivetmab）を英国で発売した。単回皮下注射で最長3カ月間の効果持続を目指す設計という。

Post-marketing reports in dogs treated with bedinvetmab (Librela™, Zoetis), the first anti-nerve growth factor (NGF) monoclonal antibody approved for canine ...

Zoetis (NYSE: ZTS) announced the launch of Lenivia (izenivetmab injection) in Canada and European Union member states. Lenivia is a long-acting monoclonal antibody therapy targeting nerve growth factor (NGF), designed to provide up to three months of osteoarthritis pain management for dogs with a single subcutaneous injection.According to Zoetis, Lenivia showed sustained pain reduction from as early as Day 7 in a pivotal nine-month European field study. The product expands Zoetis’ osteoarthritis pain portfolio alongside Rimadyl, Trocoxil and Librela, supporting veterinarians and pet owners with an additional long-term pain management option for dogs.

Zoetis (NYSE: ZTS) announced on November 26, 2025 that the European Commission granted marketing authorization for Lenivia (izenivetmab) to reduce pain associated with osteoarthritis (OA) in dogs.Lenivia is described as a long‑acting monoclonal antibody targeting nerve growth factor (NGF) that can reduce OA pain for three months with one injection. A nine‑month field study reported a safety profile with dogs showing increased mobility and decreased pain after one injection. Lenivia will join Librela (bedinvetmab) in Zoetis’ portfolio of OA pain therapies for dogs.

Zoetis (NYSE: ZTS) announced the EMA CVMP has issued a positive opinion recommending marketing authorization for Lenivia (izenivetmab) to reduce pain from osteoarthritis in dogs.The European Commission is expected to decide in Q4 2025, and Zoetis anticipates commercial availability in the EU in 2026. Lenivia is a monoclonal antibody that binds a different site on nerve growth factor and is designed to reduce OA pain for three months with one injection. A nine-month field study reported increased mobility and decreased pain after one injection.